Investigators at Massachusetts General Hospital Describe Findings in Lymphoma (Safety and Efficacy of Tisagenlecleucel In Primary Cns Lymphoma: a Phase 1/2 Clinical Trial)

Source :: Hematology Week. June 13, 2022, 18
Publication Year :: 2022
Abstract: 2022 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on Oncology - Lymphoma. According to news reporting out of Boston, [...]

Subjects :: Novartis AG -- Product development
United States. National Cancer Institute -- Reports
Massachusetts General Hospital -- Reports
Research
Reports
Product development
Clinical trials -- Research -- Reports
Pharmaceutical industry -- Product development
Drug approval -- Reports -- Research
Lymphomas -- Research
T cells -- Reports -- Research
Tisagenlecleucel -- Research -- Product development

Tools